Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$37.57

0.8 (2.18%)

10:06
10/13/17
10/13
10:06
10/13/17
10:06

Rumor: Radius Health moves up on renewed takeover chatter

  • 02

    Nov

RDUS Radius Health
$37.57

0.8 (2.18%)

05/02/17
COWN
05/02/17
DOWNGRADE
COWN
Market Perform
Radius Health downgraded to Market Perform from Outperform at Cowen
Cowen analyst Chris Shibutani downgraded Radius Health to Market Perform due to fewer near-term drivers following a proprietary expert survey regarding the outlook for Tymlos. The analyst said Tymolos has attractive features versus Forteo but differentiation is relatively limited and physicians expressed concerns over pricing and reimbursement. Further, Amgen's romosozumab's potential approval near-term and the potential entry of Forteo generic/biosimilar long-term are potential competitive threats.
05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.

TODAY'S FREE FLY STORIES

03:05
10/18/17
10/18
03:05
10/18/17
03:05
General news
FX Update: The dollar traded with a firming bias »

FX Update: The dollar…

01:45
10/18/17
10/18
01:45
10/18/17
01:45
General news
Breaking General news story  »

Vice Chairman Stanley…

SYNT

Syntel

$24.30

5.2 (27.23%)

20:37
10/17/17
10/17
20:37
10/17/17
20:37
Upgrade
Syntel rating change at William Blair »

Syntel upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 14

    Dec

QD

Qudian

20:35
10/17/17
10/17
20:35
10/17/17
20:35
Syndicate
Qudian 37.5M share IPO priced at $24.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ABT

Abbott

$55.06

0.43 (0.79%)

, USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

20:25
10/17/17
10/17
20:25
10/17/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$55.06

0.43 (0.79%)

USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

SVU

Supervalu

$19.38

0.57 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 17

    Jan

UNH

UnitedHealth

$203.89

10.69 (5.53%)

19:58
10/17/17
10/17
19:58
10/17/17
19:58
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

19:25
10/17/17
10/17
19:25
10/17/17
19:25
Conference/Events
The Heritage Foundation hosts President Trump »

President Trump speaks at…

SINA

Sina

$114.26

-0.73 (-0.63%)

19:18
10/17/17
10/17
19:18
10/17/17
19:18
Hot Stocks
Aristeia: Sina claims 'inaccurate' and 'misleading' »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLDR

Cloudera

$15.51

0.13 (0.85%)

, HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

18:57
10/17/17
10/17
18:57
10/17/17
18:57
Hot Stocks
Cloudera, Hitachi form strategic partnership »

Cloudera (CLDR) announced…

CLDR

Cloudera

$15.51

0.13 (0.85%)

HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$65.15

-1.15 (-1.73%)

18:35
10/17/17
10/17
18:35
10/17/17
18:35
Earnings
Pinnacle Financial reports Q3 adjusted EPS 90c, consensus 74c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial sees FY17 loans & deposits growth mid to high single digits »

Sees FY17 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

EXXI

Energy XXI

$8.59

-0.41 (-4.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Energy XXI provides operational update on Hurricane Nate impact »

Energy XXI provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial cuts Q4 net interest margin view to up 2-6 bp from 3-9 »

Cuts Q4 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

HGV

Hilton Grand Vacations

$39.83

0.05 (0.13%)

17:45
10/17/17
10/17
17:45
10/17/17
17:45
Hot Stocks
Hilton Grand Vacations acquires Sunrise Lodge, terms not disclosed »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

PRGX

PRGX Global

$6.80

0.05 (0.74%)

, KR

Kroger

$20.48

0.04 (0.20%)

17:42
10/17/17
10/17
17:42
10/17/17
17:42
Hot Stocks
PRGX Global signs multi-year technology services contract with Kroger »

PRGX Global (PRGX) signed…

PRGX

PRGX Global

$6.80

0.05 (0.74%)

KR

Kroger

$20.48

0.04 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 14

    Dec

UBFO

United Security Bank

$9.50

-0.05 (-0.52%)

17:38
10/17/17
10/17
17:38
10/17/17
17:38
Earnings
United Security Bank reports Q3 EPS 16c versus 12c in year-ago period »

Reports Q3 NII $8.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

, XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
Xenith Bankshares merger into Union Bankshares receives regulatory approval »

Union Bankshares (UBSH)…

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
OMA Airports reports Q3 terminal passenger traffic up 1.3% »

Aeronautical revenues per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$146.54

-0.29 (-0.20%)

17:34
10/17/17
10/17
17:34
10/17/17
17:34
Earnings
IBM sees $2.8B-$2.9B increase in Q4 sales from Q3 »

Sees $300M-$400M boost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Earnings
OMA Airports reports Q3 EPS 66c, consensus 70c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: IBM…

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

STRATA Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
IBM sees increase in gross margin of 2.5 points from Q3 to Q4 »

Says not yet feeling full…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

PAYX

Paychex

$62.90

-0.55 (-0.87%)

17:31
10/17/17
10/17
17:31
10/17/17
17:31
Syndicate
Breaking Syndicate news story on Paychex »

Paychex files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

VZ

Verizon

$48.40

0.31 (0.64%)

17:24
10/17/17
10/17
17:24
10/17/17
17:24
Hot Stocks
FCC settles New York City E-rate investigation with Verizon »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.